P/E của cổ phiếu NVS là bao nhiêu?

NOVARTIS AG ADR (NVS) hiện giao dịch ở mức P/E 23.60 lần.

ROE của cổ phiếu NVS là bao nhiêu?

NOVARTIS AG ADR có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 30.71%.

Tỷ suất cổ tức của NVS là bao nhiêu?

NOVARTIS AG ADR có tỷ suất cổ tức 2.99%.

Điểm chất lượng (Quality Score) của NVS là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của NVS ở mức 92/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu NVS không?

Điểm AI Timing của NVS là 89/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu NVS thuộc ngành nào?

NOVARTIS AG ADR được xếp vào ngành Healthcare >> Drug Manufacturers - General trên sàn NYSE

Cổ phiếu NVS (NYSE) | NOVARTIS AG ADR

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-06-30)

NVS AI Analysis Summary

Our AI summary for NVS: NOVARTIS AG ADR (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 23.60, ROE of 30.71%, a dividend yield of 2.99%. Its financial Quality Score stands at 92/100 — fundamentals stronger than most of the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

NVS

NOVARTIS AG ADR

US:NYSE STOCK Healthcare >> Drug Manufacturers - General

USD 156.15

-2.29 (-1.45%) Day Change

Watchlist Portfolio Compare Chart

23.60

P/E

1.14

D/E

30.7%

ROE

10.5%

ROA

2.99%

Div Yield

0.55

PEG

NOVARTIS AG ADR
TYPE: STOCK
MARKET: NYSE

Compare Watchlist Myport

USD 156.15 Price -2.29 (-1.45%) Day Change	NEWS SCORE: N/A

NVS Chất lượng tổng thể của cố phiếu Xuất sắc ( Chất lượng = 92) và Thời điểm mua ...(Sign In to See)...

Loading chart...

92 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Good

Reason: ROA quá thấp so với ROE

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Tốt , ...

Yếu tố Chất lượng

58%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	925
Magic Formula Rank by ROE	925
Magic Formula Rank by ROIC	1225
Price	156.15
PBV / Sector	7.18 / 2.68
Earning Per Share	6.62

PE / Sector	23.60 / 27.65
PEG or PE/Growth / Sector	0.55 / 0.28 GOOD
Average 1M Daily Value	264.00 M GREAT
Average 1W Daily Value	256.89 M GREAT

Yếu tố Kỹ thuật

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

56%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

77%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	22.93 / 17.30 GREAT
NPM Average (%) / Sector	23.90 / 17.60 GREAT
NPM Change Average (%) / Sector	17.98 / 92.67 GOOD
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	10.46 / 8.73
ROA Average (%) / Sector	11.02 / 8.56
ROA Change Average (%) / Sector	29.91 / 94.23 GREAT
ROE (%) / Sector	30.71 / 26.78 GREAT
ROE Average (%) / Sector	26.37 / 13.05 GREAT
ROE Change Average (%) / Sector	42.47 / 96.64 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

12%

Dividend (%) / Sector	2.99 / 2.40
Dividend Average (%) / Sector	3.64 / 3.39
Dividend Change Average (%) / Sector	-7.60 / 4.92

Chi tiết đăng ký

Analyze Date	2026-08-01 08:00:15
Symbol	NVS
Name	NOVARTIS AG ADR
Sector	Healthcare >> Drug Manufacturers - General
Market	NYSE
Listed Shares	1,900.71 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	301,149.26 / 256,404.20

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Lichtstrasse 35, Basel, Switzerland, 4056

Phone: 41 61 324 11 11

Website: https://www.novartis.com

Employees: 75,267

Sector: Healthcare >> Drug Manufacturers - General

Description: Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.